Helium One Global (LON: HE1) says the installation of production facilities at the Pinyon Canyon plant at the 50% owned Galactica-Pegasus helium development in Tanzania is progressing. This will increase production capacity. The share price jumped 79.3% to 0.78p.
Trading in Celsius Resources (LON: CLA) shares recommenced trading on the ASX on 9 February. This followed a successful court case over the resignation of an auditor in 2011. The share price recovered 54.8% to 1.2p.
South east Asia gas explorer Sunda Energy (LON: SNDA) has entered an unsecured loan agreement with chief executive Dr Andy Butler of up to £1.5m. The initial draw down is £400,000. This will help to fund the transaction costs for the proposed acquisition od a portfolio of oil and gas assets. A revised farm in agreement for 60% owned Timor-Leste TL-SO 19 16 PSC is being discussed with partner TIMOR GAP. The share price increased 54.8% to 0.039p.
Gift packaging and stationery supplier IG Design (LON: IGR) is trading ahead of expectations. In the nine months to December 2025, margins of 4% are at the higher end of guidance. Full year pre-tax profit estimate has been raised from $7.1m to $9.9m. Cash could be more than $55m at the end of March 2026. A new chief executive is being recruited. The full year results will be published in June and there will be a return to reporting in pounds. The share price rebounded 36.4% to 64.4p.
FALLERS
Video streaming technology developer Aferian (LON: AFRN) has extended its $16.5m banking facilities to 20 March 2026. It could be further extended at a later date. The loan from major shareholder kestrel Partners is £1.59m and is repayable on 15 April 2026. The formal sale process continues, and this is leading to significant adviser costs. Some potential options for the trading businesses would not raise as much as the bank facility. The share price slumped 69.1% to 0.4254p.
Faron Pharmaceuticals (LON: FARN) is planning to raise €40m to enable acceleration of development of its lead asset bexmarilimab and to run the Phase II portion of the FDA agreed Phase II/III trial in frontline high risk myelodysplastic syndrome. Lead asset bexmarilimab is an investigational immunotherapy designed to overcome resistance to existing cancer treatments by harnessing the power of immune cells and igniting the immune system. Management expects value inflection points in 2026 and 2027. The share price declined 67.5% to 54.5p.
Phoenix Copper (LON: PXC) has suspended chief executive Marcus Edwards-Jones and finance director Richard Wilkins due to their recent conduct and past payments. An investigation is underway. The company has limited cash available, and it will last until the second quarter of 2026. The share price halved to 1p.
Skin treatments developer SkinBioTherapeutics (LON: SBTX) chief executive has resigned after having been suspended due to investigations into his conduct. Martin Hunt has become executive chairman. There is no further comment about what has happened. Mark Dixon has raised his shareholding to 20.45%. The share price slipped 38.9% to 12.375p.